| 1 |
Halliday N, Westbrook RH. Liver transplantation: post-transplant management[J]. Br J Hosp Med (Lond), 2017，78(5):278-285.
|
| 2 |
Shaked A, DesMarais MR, Kopetskie H, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation[J]. Am J Transplant, 2019，19(5):1397-1409.
|
| 3 |
Jucaud V, Shaked A, DesMarais M, et al. Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients[J]. Hepatology, 2019，69(3):1273-1286.
|
| 4 |
Guo T, Lei J, Gao J, et al. The hepatic protective effects of tacrolimus as a rinse solution in liver transplantation: A meta-analysis[J]. Medicine (Baltimore), 2019，98(21): e15809.
|
| 5 |
Rayar M, Tron C, Locher C, et al. Tacrolimus concentrations measured in excreted bile in liver transplant recipients: the STABILE study[J]. Clin Ther, 2018，40(12):2088-2098.
|
| 6 |
Saliba F, Rostaing L, Gugenheim J, et al. Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: a randomized, multicenter study[J]. Transplantation, 2016，100(8):1705-1713.
|
| 7 |
Grigg SE, Sarri GL, Gow PJ, et al. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019，49(10):1260-1273.
|
| 8 |
Jung DH, Tak E, Hwang S, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018，24(7):932-945.
|
| 9 |
Perito ER, Martinez M, Turmelle YP, et al. Posttransplant biopsy risk for stable long-term pediatric liver transplant recipients: 451 percutaneous biopsies from two multicenter immunosuppression withdrawal trials[J]. Am J Transplant, 2019，19(5):1545-1551.
|
| 10 |
Castedal M, Skoglund C, Axelson C, et al. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation[J]. Scand J Gastroenterol, 2018，53(6):741-747.
|
| 11 |
Koo J, Wang HL. Acute, chronic, and humoral rejection: pathologic features under current immunosuppressive regimes[J]. Surg Pathol Clin, 2018，11(2):431-452.
|
| 12 |
Aibara N, Ohyama K, Hidaka M, et al. Immune complexome analysis of antigens in circulating immune complexes from patients with acute cellular rejection after living donor liver transplantation[J]. Transpl Immunol, 2018，48:60-64.
|
| 13 |
Lo RC, Chan KK, Leung CO, et al. Expression of hepatic progenitor cell markers in acute cellular rejection of liver allografts-An immunohistochemical study[J]. Clin Transplant, 2018, 32(3):e13203.
|
| 14 |
Lee M. Antibody-mediated rejection after liver transplant[J]. Gastroenterol Clin North Am, 2017，46(2):297-309.
|
| 15 |
Rodríguez-Perálvarez M, Rico-Juri JM, Tsochatzis E, et al. Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal[J]. Transpl Int, 2016，29(9):961-973.
|
| 16 |
McAlister VC. Anti-donor immunoglobulin G subclass in liver transplantation[J]. Hepatobiliary Surg Nutr, 2019，8(2):125-128.
|
| 17 |
Jadlowiec CC, Taner T. Liver transplantation: Current status and challenges[J]. World J Gastroenterol, 2016，22(18):4438-4445.
|
| 18 |
Feng S, Bucuvalas JC, Demetris AJ, et al. Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants[J]. Gastroenterology, 2018，155(6):1838-1851.
|
| 19 |
Bitar C, Olivier K, Lee C, et al. Acute graft-vs-host disease following liver transplantation[J]. Cutis, 2019，103(6):E8-E11.
|
| 20 |
马明，蒋文涛. 肝移植术后移植物抗宿主病[J/CD]. 实用器官移植电子杂志，2014, 2(4):249-252.
|